News | August 24, 2008

Vermillion Says New Study Supports its Peripheral Artery Disease Diagnostic Test Program

August 25, 2008 - Vermillion Inc. said last week a study published in the August 2008 issue of the journal Vascular Medicine included data supporting its peripheral artery disease (PAD) diagnostic program.

The study was led by John Cooke, M.D., Ph.D., professor of medicine at Stanford University and involved researchers at Stanford, Mt. Sinai Medical Center (New York) and Vermillion.

“PAD is a serious disease that often goes undiagnosed and untreated,” said Dr. Cooke. “A blood test that identifies people at risk for this debilitating condition will improve diagnosis and give these people a better chance of getting the life- and limb-saving therapy they need. Our study indicates that this biomarker panel could assist physicians in identifying those individuals at highest risk of having PAD.”

The study comprised 540 individuals: 197 individuals with both coronary artery disease and peripheral arterial disease (CAD PAD); 81 with CAD only; and 262 with no hemodynamically significant disease of the coronary or peripheral arteries. Blood plasma was analyzed for a series of candidate biomarkers, and a final biomarker panel comprising Beta-2M, cystatin C, hsCRP, and glucose had an increased association with PAD status (odds ratio = 7.3).

Vermillion has entered into an exclusive license agreement with Stanford to develop and commercialize the PAD biomarker panel.

PAD, a serious but often asymptomatic disorder affecting some eight to 12 million Americans, is caused by the buildup of fat and cholesterol, or plaque, in the peripheral arteries, disrupting normal blood flow. Left untreated, PAD more than doubles the risk of heart attack and stroke and increases the risk of amputation and death. There are treatments that can save the lives and limbs of these patients, once the disease is recognized.

For more information: www.vermillion.com

Related Content

Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init